<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction - Cote, S - 2020 | Cochrane Library</title> <meta content="Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction - Cote, S - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013559/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction - Cote, S - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013559/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013559" name="dc.identifier" scheme="DOI"/> <meta content="Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction" name="citation_title"/> <meta content="Sharlotta Cote" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Alexis Ceecee Zhang" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Victoria Ahmadzai" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Amina Maleken" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Christine Li" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Jeremy Oppedisano" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Kaavya Nair" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="Ljoudmila Busija" name="citation_author"/> <meta content="Monash University" name="citation_author_institution"/> <meta content="Laura E Downie" name="citation_author"/> <meta content="The University of Melbourne" name="citation_author_institution"/> <meta content="ldownie@unimelb.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="3" name="citation_issue"/> <meta content="10.1002/14651858.CD013559" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/03/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013559/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013559/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013559/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Dry Eye Syndromes [etiology, therapy]; Intense Pulsed Light Therapy [*methods]; Meibomian Gland Dysfunction [complications, *therapy]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013559&amp;doi=10.1002/14651858.CD013559&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="uYcNEb5O";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013559\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013559\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013559\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","zh_HANS","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013559",title:"Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction",firstPublishedDate:"Mar 18, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Eyes and Vision Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013559&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013559';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013559/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013559/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013559%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013559/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013559/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013559/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013559/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013559" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013559/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013559" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013559/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013559/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>10292 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013559" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0086"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0045"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-sec-0075"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013559/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/appendices#CD013559-sec-0091"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/table_n/CD013559StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/table_n/CD013559StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013559/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013559/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013559/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013559/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013559/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0002">Sharlotta Cote</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0003">Alexis Ceecee Zhang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0004">Victoria Ahmadzai</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0005">Amina Maleken</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0006">Christine Li</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0007">Jeremy Oppedisano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0008">Kaavya Nair</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0009">Ljoudmila Busija</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013559/information#CD013559-cr-0010"><i class="icon corresponding-author fa fa-envelope"></i>Laura E Downie</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013559/information/en#CD013559-sec-0099">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 March 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013559/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013559">https://doi.org/10.1002/14651858.CD013559</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013559-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013559-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013559-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013559-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013559-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013559-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013559-abs-0001" lang="en"> <section id="CD013559-sec-0001"> <h3 class="title" id="CD013559-sec-0001">Background</h3> <p>Meibomian gland dysfunction (MGD) is the major cause of evaporative dry eye disease, which is the more prevalent form of dry eye disease. Intense pulsed light (IPL) therapy, involving treatment of the skin near the eyelids, has emerged as a potential treatment for MGD. </p> </section> <section id="CD013559-sec-0002"> <h3 class="title" id="CD013559-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of intense pulsed light (IPL) for the management dry eye disease resulting from meibomian gland dysfunction (MGD). </p> </section> <section id="CD013559-sec-0003"> <h3 class="title" id="CD013559-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE (Ovid), Embase Ovid and three trial registers for eligible clinical trials on 1 August 2019. There were no restrictions on publication status, date or language. </p> </section> <section id="CD013559-sec-0004"> <h3 class="title" id="CD013559-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) studying the effectiveness or safety of IPL for treating MGD. </p> </section> <section id="CD013559-sec-0005"> <h3 class="title" id="CD013559-sec-0005">Data collection and analysis</h3> <p>Our outcomes of interest were the change from baseline in subjective dry eye symptoms, adverse events, changes to lipid layer thickness, tear break‐up time (TBUT), tear osmolarity, eyelid irregularity, eyelid telangiectasia, meibomian gland orifice plugging, meibomian gland dropout, corneal sodium fluorescein staining and conjunctival lissamine green staining. </p> <p>Two review authors independently screened abstracts and full‐text articles, extracted data from eligible RCTs and judged the risk of bias using the Cochrane tool. We reached consensus on any disagreements by discussion. We summarised the overall certainty of the evidence using the GRADE Working Group approach. </p> </section> <section id="CD013559-sec-0006"> <h3 class="title" id="CD013559-sec-0006">Main results</h3> <p>We included three RCTs, one from New Zealand, one from Japan and one from China, published between 2015 and 2019. Together, these trials enrolled 114 adults (228 eyes). Two studies used a paired‐eye (inter‐eye comparison) design to evaluate the effects of a sham (control) IPL treatment relative to an actual IPL treatment. One study randomised individuals to either an IPL intervention combined with meibomian gland expression (MGX), or MGX alone (standard therapy). The study follow‐up periods ranged from 45 days to nine months. None of the trials were at low risk of bias in all seven domains. The first authors of two included studies were in receipt of funding from patents or the manufacturers of IPL devices. The funding sources and declaration of interests were not given in the report of the third included trial. </p> <p>All three trials evaluated the effect of IPL on dry eye symptoms, quantified using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. Pooling data from two trials that used a paired‐eye design, the summary estimate for these studies indicated little to no reduction in dry eye symptoms with IPL relative to a sham intervention (mean difference (MD) –0.33 units, 95% confidence interval (CI) –2.56 to 1.89; I² = 0%; 2 studies, 144 eyes). The other study was not pooled as it had a unit‐of‐analysis error, but reported a reduction in symptoms in favour of IPL (MD –4.60, 95% CI –6.72 to –2.48; 84 eyes). The body of evidence for this outcome was of very low certainty, so we are uncertain about the effect of IPL on dry eye symptoms. </p> <p>There were no relevant combinable data for any of the other secondary outcomes, thus the effect of IPL on clinical parameters relevant to dry eye disease are currently unclear. </p> <p>For sodium fluorescein TBUT, two studies indicated that there may be an improvement in favour of IPL (MD 2.02 seconds, 95% CI 0.87 to 3.17; MD 2.40 seconds, 95% CI 2.27 to 2.53; 172 eyes total; low‐certainty evidence). </p> <p>We are uncertain of the effect of IPL on non‐invasive tear break‐up time (MD 5.51 seconds, 95% CI 0.79 to 10.23; MD 3.20, 95% CI 3.09 to 3.31 seconds; two studies; 140 eyes total; very low‐certainty evidence). </p> <p>For tear osmolarity, one study indicated that there may be an improvement in favour of IPL (MD –7.00 mOsmol/L, 95% –12.97 to –1.03; 56 eyes; low‐certainty evidence). </p> <p>We are uncertain of the effect of IPL on meibomian gland orifice plugging (MD –1.20 clinical units, 95% CI –1.24 to –1.16; 84 eyes; very low‐certainty evidence). </p> <p>We are uncertain of the effect of IPL on corneal sodium fluorescein staining. One study reported no evidence of a difference between the IPL and sham intervention arms at three months of follow‐up (P = 0.409), and a second study reported data favouring IPL (MD –1.00 units, 95% CI –1.07 to –0.93 units; 172 eyes in total; very low‐certainty evidence). </p> <p>We considered the incidence of adverse events at the study endpoint, as a measure of safety. As most trials did not specifically report adverse events, the safety of IPL as a treatment for MGD could also not be determined with any certainty. Very low‐certainty results from individual studies suggest some adverse effects that may be experienced by participants, include mild pain and burning, and the potential for partially losing eyelashes (due to clinician error). </p> </section> <section id="CD013559-sec-0007"> <h3 class="title" id="CD013559-sec-0007">Authors' conclusions</h3> <p>This systematic review finds a scarcity of RCT evidence relating to the effectiveness and safety of IPL as a treatment for MGD. Whether IPL is of value for modifying the symptoms or signs of evaporative dry eye disease is currently uncertain. Due to a lack of comprehensive reporting of adverse events, the safety profile of IPL in this patient population is also unclear. The current limitations in the evidence base should be considered by clinicians using this intervention to treat MGD, and outlined to individuals potentially undergoing this procedure with the intent of treating dry eye disease. </p> <p>The results of the 14 RCTs currently in progress will be of major importance for establishing a more definitive answer regarding the effectiveness and safety of IPL for treating MGD. We intend to update this review when results from these trials become available. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013559-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013559-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013559-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013559-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013559-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013559-abs-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013559-abs-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD013559-abs-0004">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013559-abs-0003" lang="en"> <h3>Intense‐pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction</h3> <p><b>Background:</b> dry eye is an eye condition that can cause eye soreness or irritation and changes to vision. One of the main causes of dry eye is known as 'meibomian gland dysfunction' (MGD), which causes problems in the meibomian glands (glands located in the eyelids). These glands produce an oily substance (known as meibum). Meibum is important for keeping the tears and surface of the eye healthy. In MGD, the meibomian glands become blocked and the meibum is abnormal. Intense pulsed light (IPL) therapy is a light treatment applied to the skin near the bottom eyelids. IPL therapy has been suggested as a treatment for MGD. </p> <p><b>Aim of the review:</b> to summarise research on the use of IPL for treating MGD. We were interested in whether the treatment improved dry eye symptoms. We considered whether there were any side effects from IPL. We were also interested in several clinical tests, such as corneal sodium fluorescein staining (a test that uses orange dye (fluorescein) to detect damage to the surface of the eye). These tests give us information about whether the treatment improves the working of the meibomian glands. </p> <p><b>Study characteristics:</b> we searched for studies that had been published up to 1 August 2019. We identified three randomised controlled trials (RCTs; clinical studies where people are randomly put into one of two or more treatment groups) involving 114 adults (228 eyes) from three countries (New Zealand, Japan and China) that had been published between 2015 and 2019. The maximum time that people in the studies were followed up for after the treatment was nine months. </p> <p><b>Key findings:</b> because of very low‐quality evidence, we are unclear about the effect of IPL on dry eye symptoms. IPL may be helpful to improve some of the clinical signs of MGD (such as tear stability and tear composition ‐ both signs of how healthy the tears produced by the eye are). We are uncertain about the effect of IPL on meibomian gland blockage or corneal sodium fluorescein staining. </p> <p>As most studies did not report side effects, we are uncertain about the safety of IPL as a treatment for MGD. Very low‐quality results from individual studies suggest there may be some side effects, including mild eye pain and burning, and partially losing eyelashes (due to mistakes when using the IPL device). </p> <p><b>Quality of the evidence:</b> the evidence for how effective and safe IPL is for treating MGD was of low or very low quality. </p> <p><b>Conclusions:</b> due to limited information in the clinical trials, we could not determine with certainty whether IPL treatment for MGD is effective or safe. The review findings indicate that more research is needed. It is important that eye care clinicians, and people considering having IPL as a dry eye treatment, are aware that there is limited high‐quality research to understand whether the procedure is effective or safe. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013559-sec-0086" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013559-sec-0086"></div> <h3 class="title" id="CD013559-sec-0087">Implications for practice</h3> <section id="CD013559-sec-0087"> <p>Based upon our consideration of the current, best‐available clinical trial evidence, we find a dearth of high‐quality evidence relating to the effectiveness or safety of IPL for treating MGD. </p> <p>Whether IPL is of value for modifying the symptoms or signs of evaporative dry eye disease is currently uncertain. Due to a lack of comprehensive reporting of adverse events, the safety profile of IPL in this patient population is also unclear. These factors should be considered by clinicians using this intervention and clearly outlined to patients potentially undergoing this procedure, to ensure an appropriate level of informed consent. </p> <p>All of the studies included in this review also excluded individuals with certain skin types (V and VI on the Fitzpatrick scale), due to the potential increased risk of adverse effects when IPL is applied to darker skin types. As a therapy, IPL is thus only applicable to individuals with skin types I to IV (Fitzpatrick scale). As this is a known caveat of the applicability of this technology more generally, this factor did not contribute to downgrading the certainty of the body of evidence. </p> <p>The relative effectiveness of IPL relative to other established treatments for MGD (e.g. thermal pulsation therapy) is also still not currently known; head‐to‐head trials are required to ascertain how IPL compares, both in terms of effectiveness and safety, to other modalities. </p> <p>The results of the 14 RCTs currently in progress will be of importance for establishing a more definitive answer regarding the effectiveness and safety of IPL for treating MGD (see <a href="./references#CD013559-sec-0107" title="">Characteristics of ongoing studies</a> table). </p> </section> <h3 class="title" id="CD013559-sec-0088">Implications for research</h3> <section id="CD013559-sec-0088"> <p>This is the first systematic review to appraise and synthesise RCT evidence relating to the effectiveness and safety of IPL for the treatment of MGD. While there have been several open‐label and non‐randomised studies of IPL that suggest that there may be a potential benefit in dry eye populations (e.g. <a href="./references#CD013559-bbs2-0031" title="AlbietzJM , SchmidKL . Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clinical and Experimental Optometry2018;101(1):23‐33. ">Albietz 2018</a>; <a href="./references#CD013559-bbs2-0051" title="GuptaPK , VoraGK , MatossianC , KimM , StinnettS . Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Canadian Journal of Ophthalmology2016;51(4):249‐53. ">Gupta 2016</a>), we only identified three relevant RCTs that collectively considered a total of 114 participants. Two of these trials used a pair‐eye design which, as discussed, has several limitations that may confound the reported findings (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). The other trial randomised individual participants to the intervention groups, but performed the data analysis using both eyes as independent samples, without statistical adjustment for within‐person correlation (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). </p> <p>There is thus a need for suitably powered, robust clinical trials to further evaluate the effectiveness and safety of IPL as a treatment for MGD. Such trials should be: of adequately powered, randomise individuals (rather than eyes) to each intervention and analyse the per‐eye data using statistically robust methods, and clearly define the patient population (including factors such as ethnicity and MGD severity using a standard classification). In view of the ties between the manufacturers or sponsors in at least two of the included trials, it would be preferable for there to be greater independence in the design, conduct and reporting of future trials in this field. Some of these issues may be addressed by the 14 trials of IPL for MGD that are currently ongoing. </p> <p>As emphasised in other systematic reviews in this field (e.g. <a href="./references#CD013559-bbs2-0041" title="DownieLE , NgS , LindsleyK , AkpekE . Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease. Cochrane Database of Systematic Reviews2019, Issue 12. [DOI: 10.1002/14651858.CD011016.pub2] ">Downie 2019</a>), there is a need to develop a 'core outcome set' for dry eye clinical trials (<a href="./references#CD013559-bbs2-0072" title="SaldanhaIJ , PetrisR , HanG , DickersinK , AkpekE . Research questions and outcomes prioritized by patients with dry eye. JAMA Ophthalmology2018;136(10):1170‐9. [DOI: 10.1001/jamaophthalmol.2018.3352] ">Saldanha 2018</a>) to improve the consistency of outcome reporting. This will enhance the ability to synthesise data in meta‐analyses, and thus draw more certain conclusions about the relative effectiveness and safety of dry eye interventions. </p> <p>The trial by <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> noted a cumulative effect from IPL treatment over 45 days; however, due to the short duration of the included studies (up to three months in <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> and six months of active intervention in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>), we were unable to explore this possibility. Longer study durations are thus required in order to determine the optimal intervention period. The timing of the clinical evaluation (including symptoms and signs), relative to the administration of the intervention should also be carefully considered. For example, <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> performed the clinical assessment prior to the intervention and <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> assessed clinical outcomes immediately post‐IPL. <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> performed the postintervention assessment one day after the intervention, and in a separate follow‐up paper reported continuous improvement in meibomian gland secretion function and tear break‐up time six months following treatment (<a href="./references#CD013559-bbs2-0071" title="RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. ">Rong 2018</a>). Separating the intervention from the assessment minimises the risk of only capturing short‐term clinical changes induced by the heating effect of IPL, as opposed to any potential longer‐term effects of the intervention. </p> <p>Due to the risk of adverse events being higher in people with darker skin tones, it would have been useful for the studies to separate the participants into subgroups to investigate whether skin type and the associated light intensities affected the effectiveness or safety (or both) outcomes. For example, if relatively higher intensities for lighter skin types had a significant effect on outcomes compared to individuals necessarily treated with lower intensity light pulses. Adverse event reporting should also be stratified by Fitzpatrick scores. </p> <p>There is also a need to more clearly establish the relative effectiveness and safety of: the different types of commercially available IPL devices, IPL relative to other MGD therapies and combining IPL with other forms of MGD management approaches. </p> <p>The mechanism of action for IPL treatment in MGD is also not yet established, and thus is an additional area requiring further research. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013559-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013559-sec-0015"></div> <div class="table" id="CD013559-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IPL (with/without MGX) compared to sham or no treatment (with/without MGX) for the treatment of meibomian gland dysfunction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IPL (± MGX) compared to sham or no treatment (± MGX) for the treatment of meibomian gland dysfunction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with meibomian gland dysfunction </p> <p><b>Setting:</b> eye care clinic or hospital<br/> <b>Intervention:</b> IPL treatment (± MGX)<sup>a</sup><br/> <b>Comparison:</b> sham (control) or no treatment (± MGX)<sup>a</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of eyes (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with sham treatment</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with IPL treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry eye symptoms</b>, measured using the SPEED score at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>2 studies reported no evidence of a difference (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>: MD 0.00 SPEED units, 95% CI –3.67 to 3.67; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>: MD –0.53 SPEED units, 95% CI –3.33 to 2.27), and one study reported a reduction in dry eye symptoms, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD –4.60, 95% CI –6.72 to –2.48). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not performed due to substantial statistical heterogeneity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> suggested there were some adverse effects, with 5 participants feeling mild pain and burning, and 1 participant experiencing an event that led to them partially missing their eyelashes "following mistakes from the doctors during treatment." However, no further details were provided. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported that 3 participants in the MGX (control) group withdrew from the study because of pain experienced during the procedure. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> did not specifically report on adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sodium fluorescein TBUT</b>, measured in seconds, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both studies reported an improvement in sodium fluorescein TBUT, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>: MD 2.02 seconds, 95% CI 0.87 to 3.17; 88 eyes; <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD 2.40 seconds, 95% CI 1.52 to 3.28, 84 eyes). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not performed due to a unit‐of‐analysis error in (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NIBUT</b>, measured in seconds, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both studies reported a relative improvement in NIBUT, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>: MD 5.50 seconds, 95% CI 0.77 to 10.23; 56 eyes; <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD 3.20 seconds, 95% CI 3.09 to 3.31; 84 eyes). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not performed due to a unit‐of‐analysis error in (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tear osmolarity</b>, measured in mOsmol/L, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>1 study found a relative improvement in tear osmolarity, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>: MD –7.00 mOsmol/L, 95% CI –12.97 to –1.30). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Meibomian gland orifice plugging</b>, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>1 study reported an inter‐group difference in extent of meibomian gland orifice plugging in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD –1.20 units, 95% CI –1.24 to –1.16, on a clinical scale from 0 to 3). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study used data from both eyes as independent samples (without appropriate within‐person correlation). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corneal sodium fluorescein staining</b>, measured using a validated clinical scale, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> reported no significant difference between intervention arms at 3 months of follow‐up (P = 0.409). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported data favouring the IPL intervention arm (MD –1.00 units, 95% CI –1.07 to –0.93, on a scale from 0 to 9). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,c,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPL:</b> intense pulsed light; <b>MD:</b> mean difference; <b>MGX:</b> meibomian gland expression; <b>NIBUT:</b> non‐invasive tear break‐up time; <b>RR:</b> risk ratio; <b>SPEED:</b> Standard Patient Evaluation of Eye Dryness; <b>TBUT:</b> tear break‐up time. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>To be eligible for inclusion, MGX had to be applied in both the intervention and comparator arms.<br/> <sup>b</sup>Downgraded one level for risk of bias, due to absence of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>.<br/> <sup>c</sup>Downgraded one level for imprecision, as data were derived from studies of relatively small sample size and all studies had units of analysis errors.<br/> <sup>d</sup>Downgraded one level for inconsistency, as there was heterogeneity in the effect among trials with different units of analysis.<br/> <sup>e</sup>Downgraded two levels for risk of bias, due to lack of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>, and incomplete reporting of adverse outcomes in all studies.<br/> <sup>f</sup>Downgraded two levels for imprecision, as data were derived from two studies of small sample size, with wide confidence intervals and unit‐of‐analysis errors.<br/> <sup>g</sup>Downgraded two levels for imprecision, as data derived from one study with a unit‐of‐analysis error and a very small sample size.<br/> <sup>h</sup>Downgraded one level for inconsistency, as the two studies reported divergent effects. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013559-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013559-sec-0016"></div> <section id="CD013559-sec-0017"> <h3 class="title" id="CD013559-sec-0017">Description of the condition</h3> <p>Dry eye disease affects approximately 350 million individuals globally, with an estimated prevalence of 5% to 50% worldwide depending upon the geographic region (<a href="./references#CD013559-bbs2-0038" title="CraigJP , NicholsKK , AkpekEK , CaffreyB , DuaHS , JooCK , et al. TFOS DEWS II definition and classification report. Ocular Surface2017;15:276‐83. [DOI: dx.doi.org/10.1016/j.jtos.2017.05.008] ">Craig 2017</a>; <a href="./references#CD013559-bbs2-0075" title="StapletonF , AlvesM , BunyaVY , JalbertI , LekhanontK , MaletF , et al. TFOS DEWS II epidemiology report. Ocular Surface2017;15(3):334‐65. [DOI: 10.1016/j.jtos.2017.05.003] ">Stapleton 2017</a>). This complex, yet ubiquitous, condition adversely affects tear film integrity, which has sequelae for the health of the ocular surface and quality of life (<a href="./references#CD013559-bbs2-0046" title="FriedmanNJ . Impact of dry eye disease and treatment on quality of life. Current Opinion in Ophthalmology2010;21(4):310‐6. ">Friedman 2010</a>). The human tear film has multiple functions, ranging from ocular lubrication to imparting optical clarity. In dry eye disease, tear film homeostasis is disrupted, leading to compositional abnormalities, including tear hyperosmolarity. Two main subtypes of dry eye disease are recognised: evaporative and aqueous‐deficient, with potential overlap in their presentation. Meibomian gland dysfunction (MGD), leading to an abnormality in the tear lipid layer, is the leading cause of evaporative dry eye disease (<a href="./references#CD013559-bbs2-0049" title="GeerlingG , BaudouinC , AragonaP , RolandoM , BoboridisK , Benitez‐del‐CastilloJ , et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting. Ocular Surface2017;15(2):179‐92. ">Geerling 2017</a>; <a href="./references#CD013559-bbs2-0076" title="TomlinsonA , BronAJ , KorbDR , AmanoS , PaughJR , PearceEI , et al. The international workshop on meibomian gland dysfunction: report of the diagnosis subcommittee. Investigative Ophthalmology and Visual Science2011;52(4):2006‐49. ">Tomlinson 2011</a>), and is the focus of this review. MGD is highly prevalent in Asian populations (<a href="./references#CD013559-bbs2-0074" title="SiakJJ , TongL , WongWL , Cajucom‐UyH , RosmanM , SawSM , et al. Prevalence and risk factors of meibomian gland dysfunction: the Singapore Malay eye study. Cornea2012;31(11):1223‐8. ">Siak 2012</a>). Other ocular (e.g. contact lens wear) and systemic factors (e.g. hormonal status and nutrition) may also contribute to the development of MGD (<a href="./references#CD013559-bbs2-0047" title="GalorA . MGD: definition versus dry eye disease, risk factors. Current Ophthalmology Reports2014;2(2):58‐64. ">Galor 2014</a>). </p> <p>The meibomian glands are located in the upper and lower eyelids and secrete meibum, an oily substance that spreads to form the outermost layer of the tear film and aids in tear stabilisation (<a href="./references#CD013559-bbs2-0059" title="KnopE , KnopN , MillarT , ObataH , SullivanDA . The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology and Visual Science2011;52(4):1938‐78. [DOI: 10.1167/iovs.10‐6997c] ">Knop 2011</a>; <a href="./references#CD013559-bbs2-0067" title="NicholsKK , FoulksGN , BronAJ , GlasgowBJ , DogruM , TsubotaK , et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science2011;52(4):1922‐9. [DOI: 10.1167/iovs.10‐6997a] ">Nichols 2011</a>). MGD is characterised by changes to the quality and quantity of secreted meibum or obstruction of the meibomian glands, or both; these changes lead to compromised tear lipid and increased tear evaporation. An increase in the concentration of specific proinflammatory mediators has also been reported in the tear film of individuals with evaporative dry eye disease (<a href="./references#CD013559-bbs2-0055" title="JacksonDC , ZengW , WongCY , MifsudE , WilliamsonNA , AngC‐S , et al. Tear interferon‐gamma as a biomarker for evaporative dry eye disease. Investigative Ophthalmology and Visual Science2016;57(11):4824‐30. ">Jackson 2016</a>). Three clinical subforms of MGD are recognised: hypersecretory, hyposecretory and obstructive, with the latter the most common (<a href="./references#CD013559-bbs2-0059" title="KnopE , KnopN , MillarT , ObataH , SullivanDA . The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology and Visual Science2011;52(4):1938‐78. [DOI: 10.1167/iovs.10‐6997c] ">Knop 2011</a>). Animal models of obstructive MGD suggest that a key pathophysiological event is hyperkeratinisation of the meibomian gland ducts (<a href="./references#CD013559-bbs2-0045" title="FoulksGN , BronAJ . Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface2003;1(3):107‐26. ">Foulks 2003</a>; <a href="./references#CD013559-bbs2-0059" title="KnopE , KnopN , MillarT , ObataH , SullivanDA . The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Investigative Ophthalmology and Visual Science2011;52(4):1938‐78. [DOI: 10.1167/iovs.10‐6997c] ">Knop 2011</a>). <a href="./references#CD013559-bbs2-0045" title="FoulksGN , BronAJ . Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocular Surface2003;1(3):107‐26. ">Foulks 2003</a> describe the process to involve the epithelial lining of the ducts undergoing hypertrophy, which reduces the lumen size, as well as shedding of epithelial cells into the meibum. Duct orifices are then recognised to become plugged by keratinised cells, with high levels of keratin present in expressed meibum. Back‐logged meibum secretions then lead to cystic dilation of the ducts and acini, followed by meibomian gland dropout as the acini atrophy from disuse in chronic cases. Meibomian gland dropout is considered to be a permanent pathological change, which can also be associated with age‐related, non‐obstructive acinar atrophy (<a href="./references#CD013559-bbs2-0036" title="BronAJ , dePaivaC , ChauhanSK , BoniniS , GabisonEE , JainS , et al. TFOS DEWS II pathophysiology report. Ocular Surface2017;15:438‐510. [DOI: 10.1016/j.jtos.2017.05.011] ">Bron 2017</a>). </p> <p>A range of different treatment options currently exists for MGD (reviewed in <a href="./references#CD013559-bbs2-0048" title="GeerlingG , TauberJ , BaudouinC , GotoE , MatsumotoY , O'BrienT , et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Investigative Ophthalmology Visual Science2011;52:2050‐64. ">Geerling 2011</a> and <a href="./references#CD013559-bbs2-0067" title="NicholsKK , FoulksGN , BronAJ , GlasgowBJ , DogruM , TsubotaK , et al. The international workshop on meibomian gland dysfunction: executive summary. Investigative Ophthalmology and Visual Science2011;52(4):1922‐9. [DOI: 10.1167/iovs.10‐6997a] ">Nichols 2011</a>, and more recently in <a href="./references#CD013559-bbs2-0057" title="JonesL , DownieL , KorbD , Benitez‐del‐CastilloJ , DanaR , DengS , et al. TFOS DEWS II management and therapy report. Ocular Surface2017;15(3):575‐628. [DOI: 10.1016/j.jtos.2017.05.006] ">Jones 2017</a>). Some of these options include artificial tears (e.g. lubricating eye drops with lipid‐containing components), MGX (which forces meibum release from the glands), and warm compresses and thermal pulsation therapy (which both aim to liquify the meibum within the meibomian glands). Omega‐3 fatty acid supplementation may also be useful as a treatment for evaporative dry eye disease (<a href="./references#CD013559-bbs2-0041" title="DownieLE , NgS , LindsleyK , AkpekE . Omega‐3 and omega‐6 polyunsaturated fatty acids for dry eye disease. Cochrane Database of Systematic Reviews2019, Issue 12. [DOI: 10.1002/14651858.CD011016.pub2] ">Downie 2019</a>; <a href="./references#CD013559-bbs2-0042" title="EpitropoulosAT , DonnenfeldED , ShahZA , HollandEJ , GrossM , FaulknerWJ , et al. Effect of oral re‐esterified omega‐3 nutritional supplementation on dry eyes. Cornea2016;35(9):1185‐91. ">Epitropoulos 2016</a>; <a href="./references#CD013559-bbs2-0060" title="KorbDR , BlackieCA , FinnemoreVM , DouglassT . Effect of using a combination of lid wipes, eye drops, and omega‐3 supplements on meibomian gland functionality in patients with lipid deficient/evaporative dry eye. Cornea2015;34(4):407‐12. ">Korb 2015</a>). The presence of dry eye symptoms is associated with a relatively thin tear lipid layer (<a href="./references#CD013559-bbs2-0034" title="BlackieCA , SolomonJD , ScaffidiRC , GreinerJV , LempMA , KorbDR . The relationship between dry eye symptoms and lipid layer thickness. Cornea2009;28:789‐94. ">Blackie 2009</a>). Broadly, these treatments aim to restore the stability of the tear film by improving lipid layer thickness or quality, or both. It has been shown that many of these treatments only impart temporary effects on patients' symptoms (<a href="./references#CD013559-bbs2-0056" title="JiangX , LvH , SongH , ZhangM , LiuY , HuX , et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. Journal of Ophthalmology2016;2016:1910694. ">Jiang 2016</a>), and act as supportive therapies that do not necessarily target the key aetiological factor(s) driving the underlying MGD. </p> </section> <section id="CD013559-sec-0018"> <h3 class="title" id="CD013559-sec-0018">Description of the intervention</h3> <p>Intense pulsed light (IPL) therapy has traditionally been used to treat dermatological conditions, in particular the vascular skin lesions that occur in rosacea (<a href="./references#CD013559-bbs2-0050" title="GoldbergDJ . Current trends in intense pulsed light. Journal of Clinical and Aesthetic Dermatology2012;5(6):45‐53. ">Goldberg 2012</a>; <a href="./references#CD013559-bbs2-0080" title="WatH , WuD , RaoJ , GoldmanM . Application of intense pulsed light in the treatment of dermatologic disease: a systematic review. Dermatological Surgery2014;40(4):359‐77. ">Wat 2014</a>). IPL uses a high‐output flash lamp, to produce a broad wavelength, non‐coherent light, typically in the range of 500 nm to 1200 nm. Specific regions of the skin are exposed to the light output for brief flashes through an interfacing gel, with the intent of inducing coagulation of the superficial blood vessels. IPL is non‐ablative (i.e. does not remove the superficial layers of the skin) but induces photothermolysis, whereby the thermal damage is limited to haemoglobin and melanin in the skin to avoid non‐specific thermal injury to surrounding anatomical structures (<a href="./references#CD013559-bbs2-0032" title="AndersonRR , ParrishRR . Selective photothermolysis: precise microsurgery by selective absorption of pulse radiation. Science1983;220:524‐7. ">Anderson 1983</a>). </p> <p>The first IPL device obtained regulatory approval from the Food and Drug Administration (FDA) in the US in 1995, for treating lower extremity telangiectasias. Over the past 20 years, there has been rapid development and proliferation of the technology, with application in multiple fields of medicine. The potential application of IPL for treating dry eye disease was a serendipitous clinical discovery, whereby it was recognised that individuals treated with IPL for rosacea, which has an association with MGD (<a href="./references#CD013559-bbs2-0079" title="VisoE , Rodríguez‐AresMD , OubiñaB , GudeF . Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Investigative Ophthalmology and Visual Science2012;53(6):2601‐6. ">Viso 2012</a>), appeared to have a concurrent reduction in their dry eye symptoms (<a href="./references#CD013559-bbs2-0077" title="ToyosR , McGillW , BriscoeD . Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction: a 3‐year retrospective study. Photomedicine and Laser Surgery2015;33(1):41‐6. ">Toyos 2015</a>). This discovery has led to the commercial development and promotion of IPL devices that are specific for dry eye treatment. Currently, the two main devices are the M22 Optima device (Lumenis Ltd, US) and the E&gt;Eye device (E‐Swin, France). For the treatment of MGD, IPL is applied to multiple (typically five or six) locations across the face, under the inferior eyelids, starting nasally and finishing temporally. Typically, a course of treatment is recommended, involving three or four IPL sessions over approximately four months. </p> <p>An individual's suitability for IPL depends on their skin pigmentation level. The Fitzpatrick Skin Types classification (<a href="./references#CD013559-bbs2-0044" title="FitzpatrickTB . Sun and skin [Soleil et peau]. Journal de Médecine Esthétique1975;2:33‐4. ">Fitzpatrick 1975</a>), which provides a measure of the skin's tolerance to sunlight and its tendency to tan or burn, is commonly used to determine whether IPL may be an appropriate intervention option. There are six Fitzpatrick Skin Types, ranging from I (very fair skin, which always burns and never tans) through to VI (black skin, which tans easily). People with darker skin tones (types V to VI) are not good candidates for IPL, due to risks of inducing hypopigmentation and scarring. Moles or other pigmentation spots on the face should also be concealed. A range of other contraindications for IPL also exist, including certain autoimmune diseases, epilepsy, history of keloid scarring and the use of photosensitising medications. Eye shields, effective in attenuating transmission of the IPL wavelengths, must also be worn by the therapist and patient, to avoid potentially permanent eye injury. </p> </section> <section id="CD013559-sec-0019"> <h3 class="title" id="CD013559-sec-0019">How the intervention might work</h3> <p>The potential mechanism(s) of action of IPL in treating MGD remain(s) unclear. Several main theories exist, as follows: </p> <p> <ul id="CD013559-list-0001"> <li> <p><b>Inducing thrombosis of telangiectatic blood vessels in the eyelids</b> </p> </li> </ul> </p> <p>Eyelid telangiectasia is a common sign in individuals with MGD (<a href="./references#CD013559-bbs2-0073" title="SchaumbergDA , NicholsJJ , PapasEB , TongL , UchinoM , NicholsKK . The international workshop on meibomian gland dysfunction: report of the subcommittee on the epidemiology of, and associated risk factors for MGD. Investigative Ophthalmology and Visual Science2011;52(4):1994‐2005. ">Schaumberg 2011</a>). It has been suggested that IPL‐induced ablation of small vessels around the eyelid margins reduces local inflammation by decreasing the level of proinflammatory mediators reaching the eyelids and meibomian glands (<a href="./references#CD013559-bbs2-0056" title="JiangX , LvH , SongH , ZhangM , LiuY , HuX , et al. Evaluation of the safety and effectiveness of intense pulsed light in the treatment of meibomian gland dysfunction. Journal of Ophthalmology2016;2016:1910694. ">Jiang 2016</a>; <a href="./references#CD013559-bbs2-0077" title="ToyosR , McGillW , BriscoeD . Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction: a 3‐year retrospective study. Photomedicine and Laser Surgery2015;33(1):41‐6. ">Toyos 2015</a>). A relatively hypoxic tissue environment has also been shown to be beneficial for meibomian gland function (<a href="./references#CD013559-bbs2-0062" title="LiuY , ChenD , ChenX , KamWR , HattonMP , SullivanDA . Hypoxia: a breath of fresh air for the meibomian gland. Ocular Surface2019;17(2):310‐7. ">Liu 2019</a>). </p> <p> <ul id="CD013559-list-0002"> <li> <p><b>Liquification of meibum</b> </p> </li> </ul> </p> <p>The temperature of the eyelids affects the physical properties of the meibum, which becomes increasingly more fluid with increasing temperature (<a href="./references#CD013559-bbs2-0065" title="NagymihályiA , DiksteinS , TiffanyJ . The influence of eyelid temperature on the delivery of meibomian oil. Experimental Eye Research2004;78(3):367‐70. ">Nagymihályi 2004</a>). The temperature at which meibum changes from a semi‐solid to liquid state is known as the phase‐transition temperature. In individuals with MGD, the composition of lipids in the meibum is altered, resulting in a higher phase‐transition temperature compared with healthy meibomian gland secretions (<a href="./references#CD013559-bbs2-0035" title="BorchmanD , FoulksGN , YappertMC , BellJ , WellsE , NeravetlaS , et al. Human meibum lipid conformation and thermodynamic changes with meibomian‐gland dysfunction. Investigative Ophthalmology &amp; Visual Science2011;52(6):3805‐17. ">Borchman 2011</a>). Warming the eyelids, such as with warm compresses, is of value for promoting meibum warming and facilitating its expression. It has been suggested that IPL may warm the skin area adjacent to the meibomian glands, allowing for enhanced expression of blocked meibum (<a href="./references#CD013559-bbs2-0040" title="DellSJ . Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol2017;11:1167‐73.. ">Dell 2017</a>; <a href="./references#CD013559-bbs2-0051" title="GuptaPK , VoraGK , MatossianC , KimM , StinnettS . Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Canadian Journal of Ophthalmology2016;51(4):249‐53. ">Gupta 2016</a>). However, this theory has been questioned by <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>, who suggested that the effect of IPL on increasing skin temperature is modest and transient. </p> <p> <ul id="CD013559-list-0003"> <li> <p><b>Reducing <i>Demodex</i> eyelid infestation</b> </p> </li> </ul> </p> <p>A potential contributor to the pathophysiology of MGD is the ectoparasite <i>Demodex</i>, which can reside in meibomian glands and consume meibum secretions (<a href="./references#CD013559-bbs2-0061" title="LiuJ , ShehaH , TsengSC . Pathogenic role of Demodex mites in blepharitis. Current Opinion Allergy Clinical Immunology2010;10:505‐10. ">Liu 2010</a>). Under physiological conditions, the number of <i>Demodex</i> mites is controlled to prevent so‐called 'infestation', which is a common feature in individuals with rosacea. <i>Demodex</i> infestation is typically accompanied by a heightened bacterial load (<a href="./references#CD013559-bbs2-0068" title="O'ReillyN , MenezesN , KavanaghK . Positive correlation between serum immunoreactivity to Demodex‐associated Bacillus proteins and erythematotelangiectatic rosacea. British Journal of Dermatology2012;167(5):1032‐6. ">O'Reilly 2012</a>), which can contribute to promoting a chronic pro‐inflammatory environment that adversely affects the eyelids, and subsequently the ocular surface. </p> <p>It has been suggested that the exoskeleton of the <i>Demodex</i> mite may be vulnerable to IPL energy (<a href="./references#CD013559-bbs2-0058" title="KirnT . Intense pulsed light eradicates Demodex mites. Skin Allergy News2002;33(1):37. ">Kirn 2002</a>). Thus, IPL might contribute to treating MGD by reducing the <i>Demodex</i> load on the eyelids, to reduce the microbial load and thus reduce the ocular surface inflammation. </p> <p> <ul id="CD013559-list-0004"> <li> <p><b>Promoting changes to meibomian gland architecture</b> </p> </li> </ul> </p> <p>One cohort study investigated the effects of IPL on the structure of dysfunctional meibomian glands. This study suggested that IPL could improve the microstructure and the macrostructure of the meibomian glands, as assessed using <i>in vivo</i> confocal microscopy (<a href="./references#CD013559-bbs2-0082" title="YinY , LiuN , GongL , SongN . Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients. Current Eye Research2018;43:308‐13. ">Yin 2018</a>). These authors hypothesised that photomodulation of the glands stimulates cell activity and intracellular changes inside the glands, as well as decreasing inflammation surrounding them (<a href="./references#CD013559-bbs2-0082" title="YinY , LiuN , GongL , SongN . Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients. Current Eye Research2018;43:308‐13. ">Yin 2018</a>). </p> <p> <ul id="CD013559-list-0005"> <li> <p><b>Photomodulation</b> </p> </li> </ul> </p> <p>Photomodulation is a process whereby light induces intracellular changes at gene or protein (or both) levels. It has been suggested that IPL may stimulate mitochondria in the tarsal plate to increase adenosine triphosphate production, modify their output of reactive oxygen species and alter their transcription factors (<a href="./references#CD013559-bbs2-0063" title="MejíaLF , GilJC , JaramilloM . Intense pulsed light therapy: a promising complementary treatment for dry eye disease. Archivos de la Sociedad Española de Oftalmología2019;94(7):331‐6. ">Mejía 2019</a>). These changes have been proposed to impart therapeutic effects on the meibomian gland acini. </p> </section> <section id="CD013559-sec-0020"> <h3 class="title" id="CD013559-sec-0020">Why it is important to do this review</h3> <p>IPL therapy has traditionally been used to treat dermatological conditions, in particular the vascular skin lesions that occur in rosacea. In recent years, this technology has been strongly marketed in multiple jurisdictions for the treatment of MGD. IPL is currently available in more than 50 countries globally, and is being offered by some eye care clinicians as a treatment for MGD, as an in‐office, multi‐visit course of clinical care. As an example of the rapid implementation of this technology into clinical practice, it is estimated that since 2014 more than 200 eye care practices have purchased IPL devices (about AUD $30,000 to AUD $s40,000) in Australia and New Zealand. </p> <p>Despite this rapid clinical uptake, very few clinical trials have been conducted to evaluate IPL as a treatment for MGD; as such, there remains substantial clinical debate regarding whether IPL is efficacious and safe for treating MGD. The treatment has some risks, which include damage to the periocular skin (e.g. depigmentation, swelling, redness), hair or eyelash loss (or both), and permanent intraocular injury (e.g. iris transillumination). The treatment is also relatively costly for patients compared to conventional treatments for MGD (such as warm compresses and eyelid massage), often involving multiple visits that incur a charge of several hundred Australian dollars. </p> <p>Recognising a need for evidence‐based guidance in relation to the use of IPL in eye care practice, primarily based upon safety concerns, the Canadian Agency for Drugs and Technologies in Health published a report, based upon a limited literature search, examining the clinical effectiveness of IPL for treating dry eye disease (<a href="./references#CD013559-bbs2-0052" title="Health Canada. Risk of thermal harm from therapeutic medical lasers, intense pulsed light and light emitting diodes. www.canada.ca/en/health‐canada/services/drugs‐health‐products/medical‐devices/activities/announcements/notice‐risk‐thermal‐harm‐therapeutic‐medical‐lasers‐intense‐pulsed‐light‐emitting‐diodes.html (accessed 16 June 2019). ">Health Canada 2016</a>). This report concluded that there was a paucity of high‐quality evidence to inform practice. </p> <p>There is thus a strong clinical need for a systematic review to consider the current, best‐available research evidence relating to the effectiveness and safety of IPL as a treatment for MGD. Given the high prevalence of dry eye disease, we consider this topic to be of substantial relevance to clinicians, researchers and the wider community, and the findings will have substantial impact, at national and international levels. The undertaking of this review is also expected to identify important evidence gaps in the field, which will inform future research. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013559-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013559-sec-0021"></div> <p>To evaluate the effectiveness and safety of intense pulsed light (IPL) for the management dry eye disease resulting from meibomian gland dysfunction (MGD). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013559-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013559-sec-0022"></div> <section id="CD013559-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013559-sec-0024"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD013559-sec-0025"> <h4 class="title">Types of participants</h4> <p>We included adults (i.e. aged 18 years or older) with MGD or evaporative dry eye disease, as defined by the study investigators. </p> </section> <section id="CD013559-sec-0026"> <h4 class="title">Types of interventions</h4> <p>We included RCTs that compared IPL therapy applied to the facial area with the intent of treating MGD or evaporative dry eye disease, relative to standard therapy (e.g. warm compresses), placebo therapy (e.g. sham IPL) or no treatment. We excluded studies where participants were assigned with any other adjunctive treatments (e.g. MGX, artificial tears), unless this co‐intervention was administered in the same dose and frequency in the comparator group. </p> </section> <section id="CD013559-sec-0027"> <h4 class="title">Types of outcome measures</h4> <section id="CD013559-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013559-list-0006"> <li> <p>Change from baseline in subjective dry eye symptoms (including dryness, foreign body sensation, burning, itching, sensitivity to light), as measured using a validated dry eye questionnaire (e.g. Standard Patient Evaluation of Eye Dryness (SPEED) or Ocular Surface Disease Index (OSDI)), at three months of follow‐up, with an acceptable follow‐up range of up to six months. </p> </li> </ul> </p> </section> <section id="CD013559-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013559-list-0007"> <li> <p>Incidence of adverse events at the study endpoint was considered as the safety outcome.</p> </li> </ul> </p> <p>We considered the following secondary outcomes, measured as the change from baseline at three months of follow‐up, with an acceptable follow‐up range of up to six months: </p> <p> <ul id="CD013559-list-0008"> <li> <p>sodium fluorescein tear break‐up time (TBUT), measured in seconds;</p> </li> <li> <p>non‐invasive tear break‐up time (NIBUT), measured in seconds;</p> </li> <li> <p>tear osmolarity, measured in milliosmoles per litre;</p> </li> <li> <p>lipid layer thickness, measured in nanometres, using tear film interferometry;</p> </li> <li> <p>eyelid irregularity, measured using a validated slit lamp scale;</p> </li> <li> <p>eyelid telangiectasia, measured using a validated slit lamp scale;</p> </li> <li> <p>meibomian gland orifice plugging, measured using a validated slit lamp scale;</p> </li> <li> <p>meibomian gland dropout (%), measured using meibography;</p> </li> <li> <p>corneal sodium fluorescein staining, measured using a validated clinical scale;</p> </li> <li> <p>conjunctival lissamine green staining, measured using a validated clinical scale.</p> </li> </ul> </p> </section> </section> </section> <section id="CD013559-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013559-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We conducted systematic searches, without language or publication year restrictions, in the following databases: </p> <p> <ul id="CD013559-list-0009"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 7), which contains the Cochrane Eyes and Vision Trials Register) in the Cochrane Library (searched from inception to 1 August 2019; <a href="./appendices#CD013559-sec-0092">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (Ovid) (search from 1946 to 1 August 2019; <a href="./appendices#CD013559-sec-0093">Appendix 2</a>); </p> </li> <li> <p>Embase Ovid (searched from 1980 to 1 August 2019; <a href="./appendices#CD013559-sec-0094">Appendix 3</a>); </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<a href="http://www.who.int/ictrp" target="_blank">www.who.int/ictrp</a>; searched 1 August 2019; <a href="./appendices#CD013559-sec-0095">Appendix 4</a>); </p> </li> <li> <p>Australian and New Zealand Clinical Trials Registry (ANZCTR) (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>; searched 1 August 2019; <a href="./appendices#CD013559-sec-0096">Appendix 5</a>); </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>; searched 1 August 2019; <a href="./appendices#CD013559-sec-0097">Appendix 6</a>). </p> </li> </ul> </p> <p>We included studies regardless of their publication status.</p> </section> <section id="CD013559-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We undertook additional searching using the bibliographies of included RCTs to identify other potentially relevant studies. We did not handsearch conference abstracts for this review, as Cochrane Eyes and Vision routinely conducts handsearching for RCTs from major ophthalmology meetings and incorporates these results into the CENTRAL database. </p> </section> </section> <section id="CD013559-sec-0033"> <h3 class="title" id="CD013559-sec-0033">Data collection and analysis</h3> <section id="CD013559-sec-0034"> <h4 class="title">Selection of studies</h4> <p>Two review authors independently screened the titles and abstracts of the papers identified via the search strategies in Covidence. Based on the study inclusion and exclusion criteria, we classified the eligibility of each record as: yes (definitely include), no (definitely exclude), or maybe (eligibility unclear). For records where at least one review author categorised the eligibility to be yes or unclear, two review authors independently assessed the full‐text reports to classify each study as definitely include or definitely exclude. A third review author assisted with resolving any disagreements, if the two review authors were unable to reach consensus. </p> </section> <section id="CD013559-sec-0035"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data, according to a standard data extraction form, for methodology, participants (including eligibility criteria), interventions and outcomes for each included study. For prespecified primary and secondary outcomes, we extracted all relevant quantitative data. When numeric data were not available, we presented the non‐numeric data. Any discrepancies in data extraction were resolved by discussion between the review authors. Data were exported into the Cochrane's statistical software, <a href="./references#CD013559-bbs2-0070" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manage (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>, by one review author and independently reviewed for accuracy by another review author. </p> </section> <section id="CD013559-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed risk of bias in the included studies according to the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 8; <a href="./references#CD013559-bbs2-0053" title="HigginsJP , AltmanDG , SterneJA . Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011a</a>). We assessed the risk of bias in the following domains: selection bias (sequence generation and allocation concealment), performance and detection bias (masking (blinding) of participants, study personnel and outcome assessors), attrition bias (incomplete outcome data), reporting bias (selective outcome reporting) and other sources of bias. Risk of bias was graded as 'low risk', 'high risk' or 'unclear risk' for each included study. We contacted study authors when clarification was required. We used the information available within the full‐text when we were unable to contact, or failed to receive any response from, study authors after one month, or the study authors were unable to provide further information. </p> </section> <section id="CD013559-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We undertook the data analyses according to the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (Chapter 9; <a href="./references#CD013559-bbs2-0039" title="DeeksJJ , HigginsJP , AltmanDG . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Deeks 2011</a>). For continuous outcomes, we reported the mean difference (MD) between the control and intervention arms, with 95% confidence intervals (CIs). </p> </section> <section id="CD013559-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the enrolled study eye of the participant. In two trials, the unit of analysis was the study eye, with individual eyes of participants randomised to either the control or intervention arm (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). However, the results presented in these papers did not appear to be derived from paired analyses, which would account for the correlation between eyes. This represents an analysis error, which limits our confidence in the reported inter‐group statistical differences. </p> <p>Where the study included data for more than one eye per participant, we aimed to follow guidelines for clustering or paired‐eye design, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013559-bbs2-0054" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). There was one trial where this was the case (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). Specifically, participants were randomly allocated to the intervention, but both eyes of each participant were included in the analysis as independent samples; this represents a 'unit‐of‐analysis' issue. As relevant information relating to the within‐person correlation was not provided in the study report and was not obtainable from the study authors, we were unable to include these data in the analyses. </p> </section> <section id="CD013559-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact study authors to clarify factors affecting the assessment of risk of bias or to obtain missing outcome data, or both. We used the information available within the full‐text whenever we were unable to contact, or failed to receive a response from, study authors after one month, or when the study authors could not provide further information. We did not impute data and relied on the data available within the study reports. </p> </section> <section id="CD013559-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We examined clinical and methodological heterogeneity by examining the variability in the design, risk of bias, characteristics of participants, interventions and outcomes among included studies. We used the Chi² test and I² statistic to assess statistical heterogeneity among included studies. We interpreted an I² value greater than 60% to indicate substantial statistical heterogeneity. </p> </section> <section id="CD013559-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>As there were fewer than 10 studies included in the meta‐analyses, we were unable to assess for potential publication biases or small‐study effects using a funnel plot. Selective outcome reporting was assessed as part of the risk of bias assessment for each included study. </p> </section> <section id="CD013559-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses for outcomes where the studies were considered similar (no heterogeneity) for their treatment, participants and intervention. We considered multiple potential sources of heterogeneity, including clinical (e.g. different aetiologies of dry eye disease), methodological (e.g. unit‐of‐analysis issues) and statistical (with a threshold of I² of 60% or less). We used a fixed‐effect model to combine the studies for analysis when there were fewer than three studies available. We presented a narrative summary of results when we did not undertake meta‐analyses due to substantial heterogeneity or insufficient reporting of data. </p> <p>In the specific context of this review, where possible we pooled data from the studies in which the unit of analysis was the study eye (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>), and have then separately reported the data from the study where both eyes of individuals were assigned to interventions and analysed as independent samples, resulting in a unit‐of‐analysis issue (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). </p> <p><a href="./full#CD013559-tbl-0001">summary of findings Table for the main comparison</a> summarises the results of the analyses, using the approach described in Chapter 11 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013559-bbs2-0054" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). The GRADE Working Group approach was adopted to grade the certainty of the evidence. Outcomes, measured between the intervention and control arms, include the change in each of: dry eye symptoms, TBUT, NITBUT, tear osmolarity, meibomian gland orifice plugging and corneal sodium fluorescein staining, as well as the incidence of adverse events with a probable link to the study intervention. </p> </section> <section id="CD013559-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We were unable to conduct subgroup analyses due to the limited number of included studies. If there are more RCTs to evaluate in updates of this review, we will perform subgroup analyses to account for potential clinical differences in studies, such as: severity of disease, type of IPL technology and duration of treatment. </p> </section> <section id="CD013559-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform a sensitivity analysis due to an insufficient number of included studies. For updates of this review, we will perform a sensitivity analysis to assess the impact of excluding studies with a high risk of bias, including lack of allocation concealment, lack of masking and a large proportion of participants lost to follow‐up (20% or more), industry funding, and unpublished studies when adequate data are available. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013559-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013559-sec-0045"></div> <section id="CD013559-sec-0046"> <h3 class="title">Description of studies</h3> <section id="CD013559-sec-0047"> <h4 class="title">Results of the search</h4> <p>The electronic searches yielded 221 records as of 1 August 2019 (<a href="#CD013559-fig-0001">Figure 1</a>). After removal of duplicates, review authors independently screened 177 titles and abstracts for potential inclusion. We classified 37 reports as potentially eligible, and these articles proceeded to full‐text screening. We excluded 13 studies (see <a href="./references#CD013559-sec-0106" title="">Characteristics of excluded studies</a> table). The main reasons for exclusion were because the study was not a RCT (eight studies) or the study used an active (rather than inert) comparator (two studies). </p> <div class="figure" id="CD013559-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD013559-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We included 10 reports from three trials in the analyses (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>; <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>), and categorised 14 records as ongoing studies from clinical trial registries (see <a href="./references#CD013559-sec-0107" title="">Characteristics of ongoing studies</a> table). No studies were awaiting classification. </p> </section> <section id="CD013559-sec-0048"> <h4 class="title">Included studies</h4> <p>A detailed description of the three trials included in this review is provided in the <a href="./references#CD013559-sec-0105" title="">Characteristics of included studies</a> table. </p> <section id="CD013559-sec-0049"> <h5 class="title">Studies</h5> <p>The included trials were conducted in Japan (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>), New Zealand (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>), and China (<a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). All trials enrolled a relatively conservative number of participants, ranging from 28 to 44 people. Two studies used a paired‐eye (inter‐eye comparison) design to evaluate the effects of the control and intervention in the same participant (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). In these two studies, one eye randomly received IPL treatment and the fellow eye received the sham treatment. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> randomised individuals to the control and intervention arms, and included data from both eyes in the analyses; this presented a unit‐of‐analysis issue. </p> <p>The lead authors of two of the included studies made declarations of interest and were in receipt of funding from manufacturers of IPL devices (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>; <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>). The lead author of <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> holds patents on IPL therapy, is a consultant for Kowa Company (Aichi, Japan) and Lumenis Japan (Tokyo, Japan) and has received financial support from TearScience (Morrisville, North Carolina, US). <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> declared France Medical, a manufacturer of IPL devices, as a funder of consumables in the trial, and the lead author declared the same company in their personal declarations of interest. The funding sources and declaration of interests were not given for <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>. </p> </section> <section id="CD013559-sec-0050"> <h5 class="title">Participants</h5> <p>The studies evaluated 228 eyes from 114 adults.</p> <p>Overall, the mean age of participants across the three RCTs was approximately 50 years. In each of the three studies there were more women than men. Full details regarding the age and sex distribution of participants is provided in the <a href="./references#CD013559-sec-0105" title="">Characteristics of included studies</a> table. </p> <p>Only one study explicitly reported the severity of dry eye disease (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>), which enrolled individuals with "mild to moderate clinical signs of MGD." </p> </section> <section id="CD013559-sec-0051"> <h5 class="title">Interventions</h5> <p>All included trials adjusted the IPL light pulse intensity to the skin type of the participant according to the Fitzpatrick grading scale (<a href="./references#CD013559-bbs2-0044" title="FitzpatrickTB . Sun and skin [Soleil et peau]. Journal de Médecine Esthétique1975;2:33‐4. ">Fitzpatrick 1975</a>). </p> <p><a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> administered IPL using the M22 system (Lumenis Inc., US), which was adjusted to the appropriate setting (ranging from 11 J/cm² to 14 J/cm²). Participants received about 13 light pulses (with slightly overlapping areas of application) from the left preauricular area, across the cheeks and nose, to the right preauricular area, with the treated area reaching up to the inferior boundary of the eye shields. The procedure was then repeated in a second pass. Participants in the intervention arm underwent eight IPL treatments at three‐week intervals. </p> <p>All participants in both groups underwent a therapeutic MGX procedure on both the superior and inferior eyelids of each eye using an Arita Meibomian Gland Compressor (Katena, Japan) every three weeks. Eye drops containing 0.4% oxybuprocaine hydrochloride were administered prior to each procedure, to minimise pain. </p> <p>After the eight MGX with or without IPL treatment sessions, all participants underwent three follow‐up examinations over the course of 11 weeks; each participant was involved in the study for 32 weeks in total. </p> <p><a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> administered IPL treatment by delivering light pulses of 14 J/cm² to 16 J/cm² to the upper and lower eyelids using the M22 system (Lumenis Inc., US). The treatment eye received IPL to the skin areas around both the upper and lower eyelids, with monthly applications over a three‐month period. The light pulses were applied to six treatment areas of the skin, while the eyes were protected by goggles. The control eye received a sham IPL therapy, using the same device, with an energy of 0 J/cm². MGX was performed immediately after IPL treatment using an Arita tarsal gland massager, in both the control (sham) and IPL treatment arms; all participants also received polyethylene glycol (lubricant) eye drops (three times daily) and local ice‐pack treatment for five minutes after the IPL intervention (to reduce skin heat or redness, or both) as co‐interventions. </p> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> used lower energy pulses, of 9 J/cm² to 13 J/cm², applied to the lower eyelid of the intervention eye using an E&gt;Eye IPL system (E‐Swin, France). IPL was administered to the skin area immediately below the lower eyelid during three separate treatment sessions every two weeks, on study days 1, 15 and 45, as per manufacturer recommendations. Treatment was applied to four areas below the eyelid while the eyes were protected by opaque goggles. The control eye received pulses from the same IPL device with a light‐blocking filter at the tip, as a sham IPL treatment. There were no co‐interventions. </p> </section> <section id="CD013559-sec-0052"> <h5 class="title">Outcomes</h5> <p>Only one study clearly specified primary and secondary outcomes (<a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). Although the three included studies included similar outcomes, the investigators did not consistently follow the same procedures and reported measurements at different time points. </p> <p>All three included studies measured subjective dry eye symptoms and quantified best‐corrected visual acuity. All measured subjective dry eye symptoms using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. This is a validated questionnaire that gives a score from 0 to 28 depending on the frequency and severity of the following symptoms: dryness, grittiness, scratchiness, irritation, burning, watering, soreness, and eye fatigue (<a href="./references#CD013559-bbs2-0066" title="NgoW , SituP , KeirN , KorbD , BlackieC , SimpsonT . Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire. Cornea2013;32(9):1204‐10.. ">Ngo 2013</a>). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> was the only study to quantify lipid layer thickness, degree of eyelid irregularity, extent of eyelid telangiectasia and degree of meibomian gland orifice plugging, and to report quantitative data relating to meibography (quantified using the Meiboscore). </p> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> measured corneal staining using fluorescein, while <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> quantified the extent of combined corneal and conjunctival fluorescein staining. Two trials measured tear stability using NIBUT (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>; <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> used the more traditional measure of TBUT, quantified involving the instillation of sodium fluorescein. <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> evaluated several other outcomes, including conjunctival staining, lipid layer grade, tear meniscus height, tear osmolarity and tear evaporation rate. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> also reported data relating to meibum grade and Schirmer test score. <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> evaluated the meibomian gland yielding secretion score (MGYSS). Only <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> explicitly reported adverse events. </p> </section> </section> <section id="CD013559-sec-0053"> <h4 class="title">Excluded studies</h4> <p>Following full‐text evaluation, we excluded 13 studies from the review. These trials are listed in the <a href="./references#CD013559-sec-0106" title="">Characteristics of excluded studies</a> table, with the primary reason for exclusion. Overall, the two main reasons were due to a non‐RCT study design (eight studies) and use of an ineligible comparator (two studies). </p> <section id="CD013559-sec-0054"> <h5 class="title">Studies awaiting classification</h5> <p>There were no studies awaiting classification.</p> </section> <section id="CD013559-sec-0055"> <h5 class="title">Ongoing studies</h5> <p>We identified 14 ongoing studies (see <a href="./references#CD013559-sec-0107" title="">Characteristics of ongoing studies</a> table). </p> </section> </section> </section> <section id="CD013559-sec-0056"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias assessment for included trials is summarised in <a href="#CD013559-fig-0002">Figure 2</a> and <a href="#CD013559-fig-0003">Figure 3</a>. Information on the risk of bias judgements for individual studies is also provided in the <a href="./references#CD013559-sec-0105" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD013559-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013559-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD013559-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013559-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD013559-sec-0057"> <h4 class="title">Allocation</h4> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> were at low risk of bias for both allocation concealment and sequence generation, while <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> was at unclear risk in both domains. Both <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> used a computer‐generated randomisation sequence to derive the treatment allocation, and email communication with the lead authors of both studies confirmed that the allocation to intervention was concealed from study investigators randomising participants to the interventions. <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> was described as "randomised" but the authors did not report how the randomisation list was generated or how the treatment allocation was administered. </p> </section> <section id="CD013559-sec-0058"> <h4 class="title">Blinding</h4> <p>For <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>, the risk of bias domains for 'blinding of participants and personnel' and 'blinding of outcome assessors' were low, as they clearly reported procedures for masking. The risk of bias in both of these domains was unclear in <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>, which was reported as a "double‐blind" study but with no further details relating to how this was achieved. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> provided no information in relation to masking. We assumed that, in the absence of reporting, personnel and outcome assessors were not masked, which corresponds to a high potential risk of bias in these domains. </p> </section> <section id="CD013559-sec-0059"> <h4 class="title">Incomplete outcome data</h4> <p>All three included studies were at low risk of attrition bias. The participant follow‐up rates for <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> were more than 80%, with relatively equal follow‐up in the two study groups and the reasons for dropout not linked to adverse events. The <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> study had 100% participant follow‐up. </p> </section> <section id="CD013559-sec-0060"> <h4 class="title">Selective reporting</h4> <p>All trials were at high risk of reporting bias. For <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>, there was retrospective registration of the study on a clinical trial registry. For both <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>, some outcomes reported in the published report were not listed in the clinical trial registry entry, and not all items listed on the trial registry were described in the publication. </p> </section> <section id="CD013559-sec-0061"> <h4 class="title">Other potential sources of bias</h4> <p>All three included studies were at low risk of other bias, as no other potential sources of bias were identified. </p> </section> </section> <section id="CD013559-sec-0062"> <h3 class="title" id="CD013559-sec-0062">Effects of interventions</h3> <p>See: <a href="./full#CD013559-tbl-0001"><b>Summary of findings for the main comparison</b> IPL (with/without MGX) compared to sham or no treatment (with/without MGX) for the treatment of meibomian gland dysfunction</a> </p> <p><a href="./full#CD013559-tbl-0001">summary of findings Table for the main comparison</a> summarises the effect of the intervention (IPL) compared with the control (sham IPL), for the prespecified outcomes. </p> <section id="CD013559-sec-0063"> <h4 class="title">Primary outcome</h4> <section id="CD013559-sec-0064"> <h5 class="title">Dry eye symptoms</h5> <p>All three trials used the SPEED questionnaire to evaluate dry eye symptoms. <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>, who compared IPL versus sham, reported dry eye symptom scores at the study endpoint (i.e. 45 days of follow‐up). <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>, who compared IPL plus MGX versus sham plus MGX reported the change from baseline in dry eye symptoms at three months of follow‐up. We pooled data from these trials, in which the unit of analysis was the study eye (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). The summary estimate for these two studies indicated little to no reduction in dry eye symptoms with IPL relative to sham (MD –0.33 SPEED units, 95% CI –2.56 to 1.89; 2 studies, 144 eyes; <a href="./references#CD013559-fig-0005" title="">Analysis 1.1</a>; <a href="#CD013559-fig-0004">Figure 4</a>). The results presented in these papers did not appear to be derived from paired analyses, which account for the correlation between eyes. Therefore, we would expect the CIs for this result to be wider had the correct, paired analysis been applied. The level of statistical heterogeneity was negligible (I² = 0%). </p> <div class="figure" id="CD013559-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), outcome: 1.1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) [units]." data-id="CD013559-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), outcome: 1.1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) [units]. </p> </div> </div> </div> <p><a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> assigned both eyes of participants to the same intervention and included them in the analysis as separate samples. This study reported SPEED scores at 24 and 32 weeks after treatment onset. The MD between intervention arms (IPL plus MGX versus MGX alone) favoured the IPL plus MGX intervention arm, with a MD of –4.60 (95% CI –6.72 to –2.48 SPEED units) at 24 weeks, and similar results at 32 weeks. </p> <p>We used the GRADE approach to judge the certainty of the body of evidence for this outcome, and downgraded the findings by three levels to very low, for risk of bias (one level, due to lack of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>), imprecision (one level, as data derived from studies of small sample size with units of analysis errors in all three trials) and inconsistency (as there was heterogeneity in the effect estimate among trials with different units of analysis). </p> </section> </section> <section id="CD013559-sec-0065"> <h4 class="title">Secondary outcomes</h4> <section id="CD013559-sec-0066"> <h5 class="title">Adverse effects</h5> <p>None of the trials comprehensively reported adverse events. The publication by <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> suggested some adverse effects were experienced by the participants, with five participants feeling mild pain and burning, and one participant experiencing an event that led to them partially losing their eyelashes "following mistakes from the doctors during treatment." These authors also indicated that none of the participants experienced inflammation, retinal damage, ocular surface, or injury to the posterior eye. <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> did not provide any details about adverse events. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported that three participants in the MGX (control) group withdrew from the study because of pain experienced during the procedure. </p> <p>The certainty of the body of the evidence for this outcome, assessed using the GRADE approach, was downgraded by three levels to very low, for risk of bias (two levels, due to lack of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and incomplete reporting of adverse outcomes in all studies) and imprecision (one level, as data derived from three studies of small sample size with unit of analyses errors). </p> <p>Traditional measurement of TBUT involves the instillation of fluorescein into the eye (<a href="./references#CD013559-bbs2-0064" title="MengherLS , BronAJ , TongeSR , GilbertDJ . Effect of fluorescein instillation on the pre‐corneal tear film stability. Current Eye Research1985;4(1):9‐12. ">Mengher 1985</a>), while NIBUT is a less‐invasive (non‐dye) method (<a href="./references#CD013559-bbs2-0037" title="ChoP , DouthwaiteW . The relation between invasive and noninvasive tear break‐up time. Optometry Visual Science1995;72:17‐22. ">Cho 1995</a>). Both methods are considered to provide measures of tear film stability, but are not interchangeable (<a href="./references#CD013559-bbs2-0081" title="WolffsohnJ , AritaR , ChalmersR , DjalilianA , DogruM , DumbletonK , et al. TFOS DEWS II diagnostic methodology report. Ocular Surface2017;15(3):539‐74. ">Wolffsohn 2017</a>). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> assessed tear stability using TBUT with sodium fluorescein, and <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> used a NIBUT; the two types of tear stability measures are considered as separate outcomes in this review. </p> </section> <section id="CD013559-sec-0067"> <h5 class="title">Sodium fluorescein tear break‐up time</h5> <p>As summarised in <a href="./references#CD013559-fig-0006" title="">Analysis 1.2</a>, <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> measured the change from baseline in TBUT, using sodium fluorescein, and found a significant inter‐group difference at three months of follow‐up favouring the IPL intervention arm (MD 2.02 seconds, 95% CI 0.87 to 3.17; 88 eyes). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>, which considered data from the individual eyes of participants as independent samples, without statistical adjustment for within‐person correlation, reported a similar change for this outcome at 24 weeks of follow‐up, favouring the IPL group (MD 2.40 seconds, 95% CI 2.27 to 2.53 seconds; 84 eyes). Due to the unit‐of‐analysis errors in both of these studies, we would expect the CIs to be wider had the correct paired analysis been used. </p> <p>The certainty of the body of evidence for this outcome, assessed using the GRADE approach, was downgraded by two levels to low, for risk of bias (one level, due to lack of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>), and imprecision (one level, as data derived from two studies of small sample size with unit of analysis errors). </p> </section> <section id="CD013559-sec-0068"> <h5 class="title">Non‐invasive tear break‐up time</h5> <p>NIBUT was reported as study endpoint values (at 45 days of follow‐up) in <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>, and as the change from baseline at 24 weeks of follow‐up in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> (<a href="./references#CD013559-fig-0007" title="">Analysis 1.3</a>). A meta‐analysis was not possible for this outcome, owing to the unit‐of‐analysis issue in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>. Both studies reported significant inter‐group differences in tear NIBUT. In <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>, NIBUT improved with IPL treatment, relative to a sham intervention (MD 5.51 seconds, 95% CI 0.79 to 10.23). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> also reported data favouring the IPL intervention arm (MD 3.20 seconds, 95% CI 3.09 to 3.31). Owing to the unit‐of‐analysis errors in both of these studies, we would expect the CIs to be wider had the correct paired analysis been used. </p> <p>The certainty of the body of evidence for this outcome, assessed using the GRADE approach, was downgraded by three levels to very low, for risk of bias (one level, due to lack of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>) and imprecision (two levels, as data derived from two studies of small sample size with wide CIs and unit‐of‐analysis errors). </p> </section> <section id="CD013559-sec-0069"> <h5 class="title">Tear osmolarity</h5> <p>One study quantified tear osmolarity (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>). These authors reported endpoint values at 45 days of follow‐up (available from their 'supplementary material' table), with a significant inter‐group difference at this time point favouring the IPL arm (MD –7.00 mOsmol/L, 95% CI –12.97 to –1.03; <a href="./references#CD013559-fig-0008" title="">Analysis 1.4</a>). Due to the unit‐of‐analysis error, we would expect that this estimate is more precise than if the correct, paired analysis had been applied. </p> <p>We used the GRADE classification to judge the certainty of the body of evidence for this outcome, and downgraded the findings by two levels to low, due to imprecision (two levels, as data derived from one study of very small sample size with a unit‐of‐analysis error). </p> </section> <section id="CD013559-sec-0070"> <h5 class="title">Lipid layer thickness</h5> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> qualitatively measured lipid layer grade (LLG) using tear film interferometry (Tearscope Plus; Keeler, UK), and reported a higher (improved) LLG at day 45 in the IPL‐treated eye, relative to the sham‐treated eye (P = 0.002). <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> did not consider this outcome. </p> <p><a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> quantified tear lipid layer thickness using the LipiView (TearScience, US) interferometry device. The authors of this study reported a relative increase in lipid layer thickness at 24 weeks of follow‐up in favour of the IPL intervention arm (MD 19.50 nm, 95% CI 13.19 to 25.82; <a href="./references#CD013559-fig-0009" title="">Analysis 1.5</a>); although, use of data from both eyes as independent samples (without appropriate adjustment for within‐person correlation) should be noted. </p> </section> <section id="CD013559-sec-0071"> <h5 class="title">Slit lamp biomicroscopy signs: eyelid irregularity, eyelid telangiectasia, eyelid thickening and meibomian gland orifice plugging </h5> <p>Although both <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> undertook slit lamp examinations as part of the clinical trial protocol, neither study considered these specific outcomes. </p> <p>We prespecified four clinical biomicroscopic signs relating to eyelid parameters as outcome measures, namely eyelid irregularity, eyelid telangiectasia, eyelid thickening and meibomian gland orifice plugging. None of the included studies reported on eyelid thickening. Only <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>, which considered outcomes in 84 eyes (42 participants), reported these specific outcome measures. </p> <p>There were no significant inter‐group differences for the extent of eyelid irregularity at 24 weeks of follow‐up (<a href="./references#CD013559-fig-0010" title="">Analysis 1.6</a>). </p> <p>At 24 weeks of follow‐up, these authors reported a relative improvement favouring the IPL treatment arm for both eyelid telangiectasia, termed 'vascularity' in the study (MD –1.30 units, 95% CI –1.50 to –1.10 on a clinical scale from 0 to 3; <a href="./references#CD013559-fig-0011" title="">Analysis 1.7</a>), and meibomian gland plugging (MD –1.20 units, 95% CI –1.24 to –1.16 on a clinical scale from 0 to 3; <a href="./references#CD013559-fig-0012" title="">Analysis 1.8</a>). The certainty of the body of evidence for the extent of meibomian gland orifice plugging was very low, downgraded one level for risk of bias (due to an absence of participant or outcome assessor masking in this study) and by two levels for imprecision (as data derived from one study of very small sample size, with a unit of analysis error). </p> </section> <section id="CD013559-sec-0072"> <h5 class="title">Meibomian gland dropout</h5> <p>Based upon the clinical trial registry entry (ACTRN12614000162617), <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> undertook meibography, however the publication reported no data. Through personal communication with the corresponding author of this study, it was revealed that the extent of meibomian gland dropout did not significantly change over the course of the study in either treatment group. <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> evaluated meibography using a four‐step 'meibomian gland score' (MGS) relating to the extent of missing tarsal glands, graded from 0 to 3 for each of the upper and lower eyelids. These authors reported that the MGS showed no significant change from baseline at the end of the treatment period in either intervention arm, but did not provide quantitative data. </p> <p><a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> used the Meiboscore (<a href="./references#CD013559-bbs2-0033" title="AritaR , ItohK , InoueK , AmanoS . Noncontact infrared meibography to document age‐related changes of the meibomian glands in a normal population. Ophthalmology2008;115(5):911‐5. ">Arita 2008</a>), graded from 0 to 3, and reported an inter‐group difference favouring the IPL intervention arm (MD –0.30, 95% CI –0.33 to –0.27; <a href="./references#CD013559-fig-0013" title="">Analysis 1.9</a>), notwithstanding the unit‐of‐analysis issue (as previously discussed). </p> </section> <section id="CD013559-sec-0073"> <h5 class="title">Corneal sodium fluorescein staining</h5> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> reported including corneal sodium fluorescein staining as an outcome measure, although there were insufficient data provided for a meta‐analysis. <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> reported no significant difference between arms at three months of follow‐up (P = 0.409). <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> did not report data relating to this outcome measure. </p> <p><a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported data favouring the IPL intervention arm relating to combined corneal and conjunctival fluorescein staining at 24 weeks of follow‐up (MD –1.00 units, 95% CI –1.07 to –0.93 on a scale from 0 to 9; <a href="./references#CD013559-fig-0014" title="">Analysis 1.10</a>). </p> <p>The certainty of the body of evidence for this outcome was very low, downgraded one level for risk of bias (due to an absence of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>), one level for imprecision (as data derived from studies of small sample size with units of analysis errors) and one level for inconsistency (as the two studies reported divergent effects). </p> </section> <section id="CD013559-sec-0074"> <h5 class="title">Conjunctival lissamine green staining</h5> <p>The methods section of <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> reported that conjunctival staining with lissamine green was assessed; however, no data were reported. Neither <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> nor <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> considered this outcome measure. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013559-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013559-sec-0075"></div> <section id="CD013559-sec-0076"> <h3 class="title" id="CD013559-sec-0076">Summary of main results</h3> <p>The objective of this systematic review was to examine the effectiveness and safety of IPL therapy for treating dry eye disease due to MGD. The main results, and judgements regarding the certainty of the body of evidence, are provided in the <a href="./full#CD013559-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We identified three eligible RCTs, which collectively evaluated outcomes in 114 participants with evaporative dry eye disease or MGD, as defined by the study authors. The study follow‐up periods were 45 days (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>), three months (<a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>), and 32 weeks (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). Two trials were paired‐eye trials, whereby IPL was applied to the 'treatment' eye and a "sham" treatment was applied to the 'control' eye (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). However, the results presented in both these studies did not appear to be derived from paired analyses, which would account for the correlation between eyes. This represents an analysis error, which limits our confidence in the reported inter‐group statistical differences. </p> <p>In <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>, a single physical MGX was also applied to both the control and treatment eyes. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> randomised individuals to either an IPL intervention combined with MGX, or MGX alone. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> included data from both eyes as independent samples, constituting a unit‐of‐analysis error. </p> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> was at low risk of bias in domains relating to selection bias, performance bias, detection bias and attrition bias. However, this study was at high risk of bias for selective outcome reporting. This trial also received funding support from the medical company (E&gt;Eye, France) that manufactured the IPL device studied in the trial. There were unclear risks of bias in the majority of domains in the <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> trial; the risk of bias was low for attrition bias and other bias for this study. The study by <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> was at high risk of bias in domains relating to masking of study participants and outcome assessors, and selective outcome reporting. </p> <p>All three trials provided data relevant to the primary outcome, change in subjective dry eye symptoms, quantified using the SPEED questionnaire. The SPEED questionnaire is considered an appropriate subjective measure for evaluating evaporative dry eye symptoms (<a href="./references#CD013559-bbs2-0043" title="FinisD , Pischel N. KonigC , HayajnehJ , BorrelliM , SchraderS , et al. Comparison of the OSDI and SPEED questionnaires for the evaluation of dry eye disease in clinical routine. Ophthalmologe2014;111:1050‐6. ">Finis 2014</a>), and suitable for use as an outcome measure in dry eye clinical trials (<a href="./references#CD013559-bbs2-0081" title="WolffsohnJ , AritaR , ChalmersR , DjalilianA , DogruM , DumbletonK , et al. TFOS DEWS II diagnostic methodology report. Ocular Surface2017;15(3):539‐74. ">Wolffsohn 2017</a>). Given dry eye disease is a symptomatic condition, changes in this parameter are considered of major clinical relevance. We performed a meta‐analysis, pooling data from the two paired‐eye trials (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). The summary estimate indicated little to no reduction in dry eye symptoms with IPL relative to sham (MD –0.33 SPEED units, 95% CI –2.56 to 1.89; 2 studies, 144 eyes; <a href="./references#CD013559-fig-0005" title="">Analysis 1.1</a>; <a href="#CD013559-fig-0004">Figure 4</a>). The level of statistical heterogeneity was negligible (I² = 0%). </p> <p><a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported a reduction in dry eye symptoms in favour of the IPL intervention, with the acknowledged limitation of the unit‐of‐analysis issue relating to including both eyes as independent samples. </p> <p>The certainty of the evidence for this outcome relating to dry eye symptoms was very low, owing to the risk of bias in the trials, imprecision and inconsistency. </p> <p>There were two outcomes relevant to tear film stability, that is, sodium fluorescein TBUT and NIBUT. Although a pooled data analysis could not be performed, individual studies reported relative improvements in tear stability with the IPL intervention, relative to the control for both outcomes. The certainty of the evidence for tear stability outcomes was low for sodium fluorescein TBUT and very low for NIBUT, owing to the risk of bias in the included trials and imprecision. </p> <p>There was limited ability to draw conclusions in relation to all other secondary effectiveness outcomes, as data derived from one study, <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>, which had a unit‐of‐analysis error (as previously outlined). The certainty of the evidence for all other secondary effectiveness outcomes was low or very low. </p> <p>In terms of potential adverse events, <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> reported several adverse events, although it was unclear which intervention group these occurred in. These authors reported that five participants felt mild pain and burning after the IPL intervention, and one participant experienced an event that led to them partially missing their eyelashes "following mistakes from the doctors during treatment." <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> did not specifically report adverse events. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported that three participants in the MGX (control) group withdrew from the study because of pain experienced during the procedure. Due to a lack of comprehensive reporting of adverse events, there was low certainty of the safety profile of IPL in this patient population. </p> <p>Overall, this systematic review identified a paucity of evidence relating to the effectiveness or safety of IPL for the treatment of MGD. </p> </section> <section id="CD013559-sec-0077"> <h3 class="title" id="CD013559-sec-0077">Overall completeness and applicability of evidence</h3> <p>This systematic review found only three RCTs evaluating the effectiveness or safety of IPL for treating MGD. The three trials included in this review considered the use of IPL, as a treatment for MGD, over treatment durations ranging from 45 days to 32 weeks. In addition to the limitation of few participants in each trial, several factors limited our ability to synthesise the available evidence, and our ability to draw more definitive conclusions surrounding the effectiveness and safety of IPL for treating MGD, in particular: </p> <section id="CD013559-sec-0078"> <h4 class="title">Type of intense pulsed light device</h4> <p>The trials used different IPL devices. <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> used the E&gt;Eye (E‐Swin) and <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> used the M22 (Lumenis) system. These devices inherently use different wavelengths and intensities of light. Although some of these details are proprietary, the M22 system is known to apply light pulses of 11 J/cm² to 16 J/cm², while the E&gt;Eye devices delivers light pulses of 9.8 J/cm² to 13 J/cm². Given the availability of only three studies, we were unable to conduct a sub‐group analysis to compare any potential device‐related differences in outcomes. Thus, it is currently not known whether different devices may yield differential therapeutic or adverse effects (or both). In addition, it has not been comprehensively investigated whether single (<a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>) or multiple (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019)</a> adjunctive in‐office MGX(s) yield more substantial clinical effects. </p> </section> <section id="CD013559-sec-0079"> <h4 class="title">Intense pulsed light protocol and skin types</h4> <p>The number and time spacing of IPL treatments, as well as the post‐intervention follow‐up time point(s), may also impact study outcomes, although this could not be determined from the available data. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> performed the examinations prior to administration of the interventions. <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> conducted the follow‐up examination directly after administering the intervention, whereas it was undertaken one day later in <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>. It is unclear whether any changes reported by <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> reflect short‐term clinical improvement (potentially due to the immediate benefit of heat generated by the IPL device) rather than long‐term physiological changes to the meibomian glands. </p> <p>All trials reported adjusting the IPL pulse intensity to the skin type of the study participants, ranked using the Fitzpatrick grading scale (from I to VI) (<a href="./references#CD013559-bbs2-0044" title="FitzpatrickTB . Sun and skin [Soleil et peau]. Journal de Médecine Esthétique1975;2:33‐4. ">Fitzpatrick 1975</a>). This procedure acknowledges that the risk of adverse events, in particular skin hypopigmentation, are significantly higher in individuals with darker skin tones when higher‐intensity light pulses are applied (<a href="./references#CD013559-bbs2-0051" title="GuptaPK , VoraGK , MatossianC , KimM , StinnettS . Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Canadian Journal of Ophthalmology2016;51(4):249‐53. ">Gupta 2016</a>). However, none of the studies provided a clear explanation regarding the protocol used to determine the intensity of treatment for the skin type of each participant. The <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> studies were ambiguous in terms of the procedures used to allocate participants to a particular IPL intensity, reporting only that it was adjusted to the Fitzpatrick skin type. <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> reported that the protocol followed the procedure recommended by the device manufacturer, and provided details in relation to the pulse intensity each skin type received. </p> <p>None of the studies reported data for each Fitzpatrick skin type. Rather, they pooled overall findings across the full cohort of participants. Therefore, it is not possible to determine whether there are differential effects relating to the effectiveness and safety of IPL in individuals with different skin tones. </p> </section> <section id="CD013559-sec-0080"> <h4 class="title">Study populations</h4> <p>The three single‐centre studies in this review considered potentially different patient populations, although specific information about ethnicity was not provided. The <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> study was undertaken in New Zealand, and recruited individuals with "mild to moderate clinical signs of MGD," but without clear definition of the clinical criteria that were adopted or whether a threshold dry eye symptom score was required. The <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> trial, undertaken in China, presumably involved Asian participants, who were enrolled on the basis of a SPEED score of at least six units, and a Meibomian Gland Yielding Secretion Score of 12 or less. The trial by <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> was performed in Japan and evaluated "the skin type of most Japanese individuals… classified as Fitzpatrick type 3," and acknowledged that the findings reported in the study may not be representative of results in individuals of other ethnicity or skin type. </p> <p>The <a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> and <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> studies enrolled participants of a similar age (mean age about 45 years), whereas participants were generally older in the <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> trial (mean age about 61 years). To date, there have been no RCTs evaluating the effectiveness or safety of IPL in children and thus the effectiveness and safety of this intervention in this population is unknown. </p> <p>The data presented in the included studies is thus insufficient for assessing whether MGD populations of different ethnicity, age, and disease severity might have differential responses to IPL. </p> </section> <section id="CD013559-sec-0081"> <h4 class="title">Inability to synthesise data</h4> <p>We were unable to conduct meta‐analyses for most of the prespecified outcomes, which significantly impacted our ability to draw definitive conclusions regarding the effectiveness or safety of IPL treating MGD. This is of concern given that in 2016, Health Canada released a warning in relation to the use of IPL devices, due to the potential risk of skin burns (<a href="./references#CD013559-bbs2-0052" title="Health Canada. Risk of thermal harm from therapeutic medical lasers, intense pulsed light and light emitting diodes. www.canada.ca/en/health‐canada/services/drugs‐health‐products/medical‐devices/activities/announcements/notice‐risk‐thermal‐harm‐therapeutic‐medical‐lasers‐intense‐pulsed‐light‐emitting‐diodes.html (accessed 16 June 2019). ">Health Canada 2016</a>). There is thus a need to ensure the safety of this therapy before its diffuse implementation in clinical practice. </p> </section> <section id="CD013559-sec-0082"> <h4 class="title">Trial design and the control (sham) intervention</h4> <p>Two trials adopted a paired‐eye design, whereby one eye of a participant received the IPL intervention and the fellow eye received a "sham" intervention (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>). Several potential limitations to this trial design, which may confound the reported findings, include: </p> <p> <ul id="CD013559-list-0010"> <li> <p>the potential for sympathetic ocular improvement, whereby performing a treatment in one eye can yield clinical improvement in the fellow eye. This phenomenon may affect the ability to detect an inter‐eye, and thus inter‐intervention, difference; </p> </li> <li> <p>the challenge of ensuring that participants are not unmasked to the intervention. For example, IPL involves the generation of substantial heat on the surface of the skin, which would be present with the active intervention but absent from the sham intervention; this differential may inadvertently unmask participants. Neither trial assessed the extent of successful masking by asking participants to guess the per‐eye treatment allocation; </p> </li> <li> <p>the assessment of ocular comfort on a 'per eye' basis is not validated, and may be challenging, thus limiting the capacity to detect changes in dry eye symptom scores. It is possible that participants may have found it challenging to individually distinguish ocular comfort changes in each eye, and rather reported an overall change to both eyes. </p> </li> </ul> </p> <p>In addition, the results presented in these papers did not appear to be derived from paired analyses, which would account for the correlation between eyes. This represents an analysis error, which limits our confidence in the reported inter‐group statistical differences. </p> </section> </section> <section id="CD013559-sec-0083"> <h3 class="title" id="CD013559-sec-0083">Quality of the evidence</h3> <p>For all effectiveness outcomes where quantitative data were available, we judged the certainty of the evidence to be very low (symptoms, NIBUT, corneal sodium fluorescein staining, extent of meibomian gland orifice plugging and adverse events) or low (sodium fluorescein TBUT and tear osmolarity) using the GRADE approach. The main reasons for downgrading the certainty of the findings were due to risks of bias (e.g. the absence of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>), imprecision (as data derived from a limited number of studies of modest sample size) and inconsistency (due to heterogeneity in effects). </p> <p>There is currently a paucity of data relating to the safety of IPL for treating MGD.</p> </section> <section id="CD013559-sec-0084"> <h3 class="title" id="CD013559-sec-0084">Potential biases in the review process</h3> <p>We used the standard methodological procedures recommended in the<i>Cochrane Handbook for Systematic Reviews of Interventions</i> to minimise any potential source of bias during the review process (<a href="./references#CD013559-bbs2-0054" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011b</a>). </p> <p>The review protocol was prospectively registered (<a href="./references#CD013559-bbs2-0083" title="DownieLE , AhmdzaiV , CoteS , LiC , LiA , MalekenA , et al. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction: a systematic review. www.crd.york.ac.uk/prospero/display_record.php?ID=CRD420180993592018. ">Downie 2018</a>, CRD42018099359), and as such all outcome measures were specified in advance of undertaking the review. An a priori search strategy was developed that was comprehensive and did not exclude grey or non‐English literature, minimising selection bias. Two review authors independently oversaw each stage of the review process. </p> <p>We acknowledge the potential limitations of including paired‐eye studies that did not account for contralateral eye effects, and that these studies did not appear to undertake paired statistical analyses. Given the limited high‐quality data available, we opted to include these studies in the review and to report their findings, notwithstanding the potential limitations. </p> </section> <section id="CD013559-sec-0085"> <h3 class="title" id="CD013559-sec-0085">Agreements and disagreements with other studies or reviews</h3> <p>This is, to our knowledge, the first systematic review to evaluate the effectiveness and safety of IPL for treating MGD. </p> <p>In the Tear Film and Ocular surface Society (TFOS) International Dry Eye WorkShop II (DEWS II), involving a comprehensive narrative synthesis of current modalities for treating and managing dry eye disease (<a href="./references#CD013559-bbs2-0057" title="JonesL , DownieL , KorbD , Benitez‐del‐CastilloJ , DanaR , DengS , et al. TFOS DEWS II management and therapy report. Ocular Surface2017;15(3):575‐628. [DOI: 10.1016/j.jtos.2017.05.006] ">Jones 2017</a>), the authors described results from three publications (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>; <a href="./references#CD013559-bbs2-0051" title="GuptaPK , VoraGK , MatossianC , KimM , StinnettS . Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Canadian Journal of Ophthalmology2016;51(4):249‐53. ">Gupta 2016</a>; <a href="./references#CD013559-bbs2-0078" title="VeguntaS , PatelD , ShenJF . Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea2016;35(3):22. ">Vegunta 2016</a>). The studies by <a href="./references#CD013559-bbs2-0051" title="GuptaPK , VoraGK , MatossianC , KimM , StinnettS . Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Canadian Journal of Ophthalmology2016;51(4):249‐53. ">Gupta 2016</a> and <a href="./references#CD013559-bbs2-0078" title="VeguntaS , PatelD , ShenJF . Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea2016;35(3):22. ">Vegunta 2016</a> were excluded from the present review, as they are not RCTs. </p> <p>In 2018, the Canadian Agency for Drugs and Technologies in Health published a 'Rapid Response Report: Summary with Critical Appraisal' (<a href="./references#CD013559-bbs2-0069" title="RennickS , AdcockL . Intense Pulsed Light Therapy for Meibomian Gland Dysfunction: a Review of Clinical Effectiveness and Guidelines. Ottawa (Canada): Canadian Agency for Drugs and Technologies in Health, 2018. ">Rennick 2018</a>). This review involved a limited literature search of three electronic databases, and applied no methodological restrictions. This review, which included four studies, noted that most studies lacked suitable control populations for comparing the effectiveness and safety of IPL. Consistent with the present review, <a href="./references#CD013559-bbs2-0069" title="RennickS , AdcockL . Intense Pulsed Light Therapy for Meibomian Gland Dysfunction: a Review of Clinical Effectiveness and Guidelines. Ottawa (Canada): Canadian Agency for Drugs and Technologies in Health, 2018. ">Rennick 2018</a> also noted that there is no consistent protocol for performing IPL to manage MGD, and the number of treatments required to impart therapeutic benefit remains unclear. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013559-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD013559-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD013559-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD013559-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), outcome: 1.1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) [units]." data-id="CD013559-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), outcome: 1.1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) [units]. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 2 Sodium fluorescein tear break‐up time at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 2 Sodium fluorescein tear break‐up time at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 3 Non‐invasive tear break‐up time (NIBUT) at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 3 Non‐invasive tear break‐up time (NIBUT) at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 4 Tear osmolarity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 4 Tear osmolarity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 5 Lipid layer thickness at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 5 Lipid layer thickness at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 6 Eyelid irregularity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 6 Eyelid irregularity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 7 Eyelid telangiectasia at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 7 Eyelid telangiectasia at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 8 Meibomian gland orifice plugging at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 8 Meibomian gland orifice plugging at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 9 Meibomian gland dropout at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 9 Meibomian gland dropout at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013559-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/urn:x-wiley:14651858:media:CD013559:CD013559-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_t/tCD013559-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 10 Corneal sodium fluorescein staining at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months)." data-id="CD013559-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy), Outcome 10 Corneal sodium fluorescein staining at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013559/media/CDSR/CD013559/image_n/nCD013559-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013559-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IPL (with/without MGX) compared to sham or no treatment (with/without MGX) for the treatment of meibomian gland dysfunction</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>IPL (± MGX) compared to sham or no treatment (± MGX) for the treatment of meibomian gland dysfunction</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with meibomian gland dysfunction </p> <p><b>Setting:</b> eye care clinic or hospital<br/> <b>Intervention:</b> IPL treatment (± MGX)<sup>a</sup><br/> <b>Comparison:</b> sham (control) or no treatment (± MGX)<sup>a</sup> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of eyes (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk with sham treatment</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk with IPL treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dry eye symptoms</b>, measured using the SPEED score at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>2 studies reported no evidence of a difference (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>: MD 0.00 SPEED units, 95% CI –3.67 to 3.67; <a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>: MD –0.53 SPEED units, 95% CI –3.33 to 2.27), and one study reported a reduction in dry eye symptoms, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD –4.60, 95% CI –6.72 to –2.48). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228 (3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not performed due to substantial statistical heterogeneity.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Incidence of adverse events</b> at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> suggested there were some adverse effects, with 5 participants feeling mild pain and burning, and 1 participant experiencing an event that led to them partially missing their eyelashes "following mistakes from the doctors during treatment." However, no further details were provided. <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported that 3 participants in the MGX (control) group withdrew from the study because of pain experienced during the procedure. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>c,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a> did not specifically report on adverse events. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Sodium fluorescein TBUT</b>, measured in seconds, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both studies reported an improvement in sodium fluorescein TBUT, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a>: MD 2.02 seconds, 95% CI 0.87 to 3.17; 88 eyes; <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD 2.40 seconds, 95% CI 1.52 to 3.28, 84 eyes). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not performed due to a unit‐of‐analysis error in (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NIBUT</b>, measured in seconds, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Both studies reported a relative improvement in NIBUT, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>: MD 5.50 seconds, 95% CI 0.77 to 10.23; 56 eyes; <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD 3.20 seconds, 95% CI 3.09 to 3.31; 84 eyes). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Meta‐analysis was not performed due to a unit‐of‐analysis error in (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Tear osmolarity</b>, measured in mOsmol/L, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>1 study found a relative improvement in tear osmolarity, in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0002" title="ACTRN12614000162617 . Effect of intense pulsed light technology in treating meibomian gland dysfunction (MGD). anzctr.org.au/Trial/Registration/TrialReview.aspx?id=365741 (first received 4 February 2014). CraigJ , TurnbullP , ChenA . Placebo‐controlled trial of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD). Clinical and Experimental Ophthalmology2014;1:66. [DOI: 10.1111/ceo.12449] CraigJP , ChenYH , TrunbullPR . Cumulative effect of intense pulsed light (IPL) therapy for meibomian gland dysfunction (MGD) confirmed in prospective, double‐masked, placebo controlled trial. Investigative Ophthalmology and Visual Science2015;56(7):6194. CraigJP , ChenYH , TurnbullPR . Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Investigative Ophthalmology and Visual Science2015;56(3):1965‐70. [DOI: 10.1167/iovs.14‐15764] ">Craig 2015</a>: MD –7.00 mOsmol/L, 95% CI –12.97 to –1.30). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>g</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Meibomian gland orifice plugging</b>, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>1 study reported an inter‐group difference in extent of meibomian gland orifice plugging in favour of the IPL intervention (<a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>: MD –1.20 units, 95% CI –1.24 to –1.16, on a clinical scale from 0 to 3). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84 (1 study)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,h</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This study used data from both eyes as independent samples (without appropriate within‐person correlation). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Corneal sodium fluorescein staining</b>, measured using a validated clinical scale, at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><a href="./references#CD013559-bbs2-0003" title="ChiCTR‐INR‐16010256 . Therapeutic effect of intense pulsed light therapy on meibomian gland dysfunction. chictr.org.cn/showprojen.aspx?proj=17444 (first received 26 December 2016). LiuR , RongB , TuP , TangY , SongW , ToyosR , et al. Analysis of cytokine levels in tears and clinical correlations after intense pulsed light treating meibomian gland dysfunction. American Journal of Ophthalmology2017;183:81‐90. [DOI: 10.1016/j.ajo.2017.08.021] RongB , TangY , LiuR , TuP , QiaoJ , SongW , et al. Long‐term effects of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(10):562‐7. RongB , TangY , TuP , LiuR , QiaoJ , SongW , et al. Intense pulsed light applied directly on eyelids combined with meibomian gland expression to treat meibomian gland dysfunction. Photomedicine and Laser Surgery2018;36(6):326‐32. [DOI: 10.1089/pho.2017.4402] RongB , TuP , TangY , LiuRX , SongWJ , YanXM . Evaluation of short‐term effect of intense pulsed light combined with meibomian gland expression in the treatment of meibomian gland dysfunction. Chung‐Hua Yen Ko Tsa Chih [Chinese Journal of Ophthalmology]2017;53(9):675‐81. [DOI: 10.3760/cma.j.issn.0412‐4081.2017.09.008] ">Rong 2017</a> reported no significant difference between intervention arms at 3 months of follow‐up (P = 0.409). <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a> reported data favouring the IPL intervention arm (MD –1.00 units, 95% CI –1.07 to –0.93, on a scale from 0 to 9). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172 (2 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>b,c,h</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>IPL:</b> intense pulsed light; <b>MD:</b> mean difference; <b>MGX:</b> meibomian gland expression; <b>NIBUT:</b> non‐invasive tear break‐up time; <b>RR:</b> risk ratio; <b>SPEED:</b> Standard Patient Evaluation of Eye Dryness; <b>TBUT:</b> tear break‐up time. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>To be eligible for inclusion, MGX had to be applied in both the intervention and comparator arms.<br/> <sup>b</sup>Downgraded one level for risk of bias, due to absence of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>.<br/> <sup>c</sup>Downgraded one level for imprecision, as data were derived from studies of relatively small sample size and all studies had units of analysis errors.<br/> <sup>d</sup>Downgraded one level for inconsistency, as there was heterogeneity in the effect among trials with different units of analysis.<br/> <sup>e</sup>Downgraded two levels for risk of bias, due to lack of participant or outcome assessor masking in <a href="./references#CD013559-bbs2-0001" title="AritaR , FukuokaS , MorishigeN . Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocular Surface2019;17(1):104‐10. [DOI: 10.1016/j.jtos.2018.11.004] ">Arita 2019</a>, and incomplete reporting of adverse outcomes in all studies.<br/> <sup>f</sup>Downgraded two levels for imprecision, as data were derived from two studies of small sample size, with wide confidence intervals and unit‐of‐analysis errors.<br/> <sup>g</sup>Downgraded two levels for imprecision, as data derived from one study with a unit‐of‐analysis error and a very small sample size.<br/> <sup>h</sup>Downgraded one level for inconsistency, as the two studies reported divergent effects. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">IPL (with/without MGX) compared to sham or no treatment (with/without MGX) for the treatment of meibomian gland dysfunction</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013559/full#CD013559-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013559-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Subjective dry eye symptoms, as measured using a validated dry eye questionnaire at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Unit of analysis was study eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.33 [‐2.56, 1.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unit of analysis was study participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐6.72, ‐2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Sodium fluorescein tear break‐up time at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Unit of analysis was study eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Unit of analysis was study participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Non‐invasive tear break‐up time (NIBUT) at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Unit of analysis was the study eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Unit of analysis was the study participant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Tear osmolarity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Lipid layer thickness at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Eyelid irregularity at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Eyelid telangiectasia at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Meibomian gland orifice plugging at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Meibomian gland dropout at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Corneal sodium fluorescein staining at 3 months of follow‐up (with an acceptable follow‐up range ≤ 6 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Intense pulsed light (IPL) (with/without standard therapy) versus sham (with/without standard therapy)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013559/references#CD013559-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013559&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013559-note-0002">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013559-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013559-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD013559-note-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD013559-note-0001">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013559-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013559\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013559"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013559\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013559\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013559"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013559\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013559"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013559\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013559\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013559"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=uYcNEb5O&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013559&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013559';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013559/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013559/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013559%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740726839962"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013559/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740726839966"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013559/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e9d771986f480',t:'MTc0MDcyNjg0MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 